Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation | Novartis | Ongoing | Ruxolitinib (INC424) (Jakavi) | 3 | CINC424D2301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Phase II/III randomized multicentre study comparing neoadjuvant chemoradiotherapy followed by consolidation chemotherapy to neoadjuvant chemoradiotherapy alone in non-metastatic rectal cancer patients. | King Abdullah Medical City, Makkah | Ongoing | Capecitabine / oxaliplatin / FOLINIC Acid / FLUOROURACIL | 2 | IRB#17-329 version2 | King Abdullah Medical City (Makkah) |
| <p style="text-align: justify;">Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of<br />Transfusional Iron Overload in Patients with Sickle Cell Disease<br />or Other Anemias</p> | ApoPharma | Ongoing | Deferiprone | 3b | LA38-EXT | Aseer Central Hospital |
| Cholecalciferol supplementation in critically ill patients with severe vitamin D deficiency in intensive care unit – a randomized controlled trial | King Abdullah Medical City, Makkah | Ongoing | VITAMIN D3 (CHOLECALCIFEROL) | 3 | IRB#16-252, V2 | King Abdullah Medical City (Makkah) |
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation | Novartis | Ongoing | Ruxolitinib (INC424) (Jakavi) | 3 | CINC424C2301 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor Burden Follicular Lymphoma | Archigen Biotech Limited | Ongoing | Rituximab/ SAIT101 | 3 | AGB 002 | Prince Sultan Military Medical City (Riyadh), King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam) |
| "A PHASE 2/3, MULTICENTER, MULTINATIONAL,OPEN-LABEL STUDY TO EVALUATE THE EFFICACY ANDSAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUMCOFACTOR DEFICIENCY (MOCD) TYPE A" | Alexion | Ongoing | ALXN1101( Cyclic pyranopterin monophosphate monohydrobromide dihydrate) | 2b | ALXN1101-MCD-202 | King Fahad Medical City (Riyadh) |
| A Phase 4, Double-Blind, Randomised, Placebo-Controlled Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction with Surgery in Subjects with Moderate to Severe Hidradenitis Suppurativa | AbbVie | Ongoing | Adalimumab | 4 | M15-574 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| AfME Registry on GastroIntestinal Stromal Tumors (GIST) – A Retrospective Patients’ Profile Description and Evaluation of the Use of Tyrosine Kinase Inhibitors | Africa Middle East Cancer Intergroup (AMCI) | Ongoing | - | 4 | WI210066 | King Fahad Medical City (Riyadh) |
| Post-Authorization Safety Reporting Program of Canagliflozin-based Therapy in Patients With Type 2 Diabetes in Saudi Arabia | Janssen-Cilag International NV | Ongoing | canagliflozin | 4 | 28431754DI | Specialized Medical Center (Riyadh), Dr. Soliman Fakeeh Hospital (Jeddah), International Medical Center (Jeddah), Dallah Hospital (Riyadh), Almana Hospital (Jubail), Almouasa Hospital (Qatif), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh), Saudi German Hospital (Jeddah) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.